You are here: Industry Insights > Novartis

News List

Novartis and Forendo enter into tissue hormone-focused licensing collaboration pharmaceutical-technology
December 16, 2019
Finland-based Forendo Pharma has announced it has signed a licensing and collaboration agreement with Novartis.
FDA agrees to review Novartis’ sBLA of Xolair to treat nasal polyps pharmaceutical-technology
December 16, 2019
The US Food and Drug Administration (FDA) has agreed to review a supplemental biologics license application (sBLA) submitted by Novartis to seek approval for Xolair (omalizumab) to treat nasal polyps.
Sanofi ends research in diabetes, narrows units to spur profit expresspharma
December 12, 2019
Sanofi SA said recently that it would end its research efforts in diabetes and cardiovascular diseases as part of a revamp that will narrow the number of its business units in the hope of bolstering growth and profit.
Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters worldpharmanews
December 12, 2019
Novartis holded an investor event in London to provide a comprehensive overview of the company’s progress in advancing its industry-leading R&D pipeline.
Novartis Kymriah demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting pharmaceutical-business-review
December 12, 2019
Novartis announced results from two analyses of real-world experience with Kymriah (tisagenlecleucel), the only CAR-T cell therapy approved in two distinct indications.
Novartis Hosts R&D Day americanpharmaceuticalreview
December 09, 2019
Novartis held an investor event in London to provide a comprehensive overview of the company’s progress in advancing its R&D pipeline.
US FDA approves generic versions of Novartis blockbuster MS treatment expresspharma
December 09, 2019
The US Food and Drug Administration approved three generic versions of Swiss drugmaker Novartis AG’s top-selling multiple sclerosis (MS) medicine Gilenya.
Novartis partners with Amazon for digital boost to manufacturing pharmaceutical-technology
December 09, 2019
Novartis will leverage AWS services to improve manufacturing operations and efficiencies. Credit: Tony Webster.
FDA approves generics of Novartis multiple sclerosis drug Gilenya pharmaceutical-technology
December 09, 2019
The US Food and Drug Administration (FDA) has approved the first generic versions of Novartis multiple sclerosis drug Gilenya (fingolimod).
Novartis is first to recall generic Zantac after confirming suspected carcinogen fiercepharma
September 26, 2019
The Swiss drugmaker said it has not received any reports of adverse events related to use of the product as part of this recall but acknowledged NDMA is suspected of causing cancer.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page